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Local recurrence of glioblastomas is a major cause of patient mortality after definitive treatment. This review discusses the roles of the
chemokine stromal cell-derived factor-1 and its receptor CXC chemokine receptor 4 (CXCR4) in affecting the sensitivity of
glioblastomas to irradiation. Blocking these molecules prevents or delays tumour recurrence after irradiation by inhibiting the
recruitment of CD11bþ monocytes/macrophages that participate in revascularising the tumour. We review the literature pertaining
to the mechanism by which revascularisation occurs following tumour irradiation using experimental models. Areas of interest and
debate in the literature include the process by which endothelial cells die after irradiation and the identity/origin of the cells that
reconstitute the tumour blood vessels after injury. Understanding the processes that mediate tumour revascularisation will guide the
improvement of clinical strategies for preventing recurrence of glioblastoma after irradiation.
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Despite advances in techniques for administering radio-
therapy, local recurrence of glioblastomas (GBMs) typically leads
to patient mortality. In this review, we focus on the chemokine
stromal cell-derived factor-1/CXC chemokine ligand 12 (SDF-1/
CXCL12) and its receptor CXCR4 in affecting the sensitivity of
GBM to irradiation. We begin with an overview of the discovery
and characterisation of these molecules, followed by an exami-
nation of their role in tumour metastasis and tissue injury.
Finally, we discuss the data and controversies surrounding
their role in revascularisation and tumour recurrence. Our
understanding of the role of SDF-1 and CXCR4 in tumour
recurrence post irradiation is largely gained from pre-clinical
studies using mouse xenografts of human tumours. The pre-
clinical data will be the focus of this review. Clinical studies in this
area are limited, but serve as an exciting area for future
investigation.
The CXC chemokine family has multiple roles in leukocyte
migration, immune response, angiogenesis, and tumour metasta-
sis. CXC chemokines have four highly conserved cystine amino-
acid residues, with a non-conserved amino acid separating the
first two cystine residues. A second structural domain deter-
mines their function. The CXC chemokine family contains both
angiogenesis-promoting and angiogenesis-inhibiting molecules.
Stromal cell-derived factor-1 is regarded as an angiogenesis-
promoting chemokine.
Stromal cell-derived factor-1 is a small pro-inflammatory
chemoattractant cytokine that was first cloned by Tashiro et al,
1993, as a protein captured by its specific amino-terminal signal
sequences. It was later identified functionally as a molecule
involved in B-cell lymphopoiesis using an expression cloning
strategy. Human CXCR4 was initially identified as a receptor for
SDF-1 by screening chemokine receptor orphan genes for their
ability to induce intracellular Ca
2þ in response to human SDF-1.
The mouse CXCR4 receptor was subsequently found by cloning
candidate chemokine receptors and comparing the amino acid
sequence with the human cDNA (Nagasawa et al, 1998). Recently,
it has been shown that SDF-1 binds to another receptor, CXCR7
(Burns et al, 2006). This finding has opened up new possibilities
for understanding the biology of SDF-1 and modulating SDF-1-
mediated pathways.
Mice with genetic deletion of SDF-1 or CXCR4 are embryonic
lethal and have defects in embryogenesis, haematopoiesis, cardiac
ventricular septum formation, migration of neural precursors in
the cerebellum, and blood vessel formation in the gastrointestinal
tract (Nagasawa et al, 1998; Tachibana et al, 1998). The similar
phenotypes of these mice suggest that CXCR4 may be the critical
receptor through which SDF-1 acts during development. In the
adult mouse, SDF-1 expression is found in lymphoid (bone
marrow, thymus, and spleen) and non-lymphoid organs (brain,
heart, lung, liver, kidney, stomach, and intestine). In the blood,
CXCR4 expression has been described in peripheral blood
monocytes, neutrophils, lymphocytes, and haematopoietic pro-
genitors (Nagasawa et al, 1998), and has been shown to be involved
in cell migration. Stromal cell-derived factor-1 has also been
shown to induce migration of brain microglia and astrocytes
(Tanabe et al, 1997). In the adult, SDF-1 functions as a
chemoattractant for haematopoietic cells (Aiuti et al, 1997).
In addition to its role in chemotaxis, the SDF-1/CXCR4 pathway
has been reported to be a survival factor for human glioma
cells through its upregulation of the PI3K/AKT pathway (Zhou
et al, 2002).
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www.bjcancer.comCXC chemokine receptor 4 is a seven-transmembrane G-protein-
coupled receptor that acts as a receptor for SDF-1 and is also a
co-receptor for HIV entry into target cells. A discussion of CXCR4’s
role in HIV is beyond the scope of this review. We will instead
briefly review what is known about signal transduction downstream
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to phosphorylation of ERK2 and protein kinase B, coupled with
activation of PI3-kinase and formation of PIP3 (Tilton et al, 2000).
Stromal cell-derived factor-1-mediated signalling through CXCR4
has also been shown to mediate phosphorylation of focal adhesion
proteins such as RAFTK, paxillin, and Crk, and transcriptional
activation through p44/42 MAP kinase (Erk 1 and 2), and activation
of NF-kB( G a n j uet al, 1998). As our current understanding of
intracellular signalling pathways downstream of CXCR4 is largely
through in vitro studies, it is not well understood to what extent these
multiple signal transduction pathways are shared among the different
cell types or between normal vs malignant cells.
THE SDF-1/CXCR4 PATHWAY IN TUMOUR
METASTASIS AND TISSUE INJURY
The interaction between the CXCR4 receptor and its ligand,
SDF-1a, has been shown to mediate tumour metastasis (Muller
et al, 2001; Sun et al, 2005). Overexpression of CXCR4 has been
detected in a variety of human malignancies, including breast,
pancreatic, prostate cancer, and GBM. Muller et al (2001)
demonstrated that CXCR4 is expressed in primary breast cancer
cells and that SDF-1 was highly expressed in the most common
sites of metastasis, including the lymph nodes, lungs, liver, and
bone. When the CXCR4/SDF-1 interaction was blocked with a
neutralising anti-CXCR4 antibody using an in vivo xenotransplant
model, metastatic load was significantly reduced (Muller et al,
2001). These data support the role of the SDF-1/CXCR4 pathway in
the formation of metastasis for some tumours.
The SDF-1/CXCR4 pathway is also involved in tissue repair
(Kollet et al, 2003; Ratajczak et al, 2003). Kollet et al (2003)
showed that CCl4-mediated liver injury led to an increase in the
recruitment of human CD34
þ progenitor cells by SDF-1 to the
injured liver in NOD/SCID mice, suggesting that SDF-1 may direct
haematopoietic progenitor cells to sites of tissue injury. However,
whether these cells in the liver represent functional haematopoietic
stem/progenitor cells (capable of reconstituting lethally irradiated
hosts) was not examined. Chemotaxis of CXCR4-expressing
murine muscle satellite cells towards SDF-1 has also been
demonstrated, suggesting that migration of tissue-specific stem
cells may be regulated by SDF-1 (Ratajczak et al, 2003).
THE ROLE OF SDF-1/CXCR4 IN RESTORING
FUNCTIONAL VASCULATURE IN IRRADIATED GBMS
Radiotherapy has a crucial role in the treatment of GBMs, but
despite the very high radiation doses that can be delivered with
new techniques such as high-dose boost stereotactic radiosurgery,
the tumours invariably recur, leading to mortality in 75% of
patients by 2 years after initial diagnosis. As most of the recur-
rences occur within the radiation field (Minniti et al, 2010;
McDonald et al, 2010), any method of improving local control of
the primary tumour by radiotherapy would improve the curability
of patients with GBM. We have recently proposed that the cure
rates for this malignancy might be improved by targeting the
SDF-1/CXCR4 pathway, thereby preventing reconstitution of the
tumour vasculature following irradiation.
In theory, reestablishing the tumour vasculature after radiation
could be mediated either by sprouting angiogenesis (from adjacent
blood vessels) or by circulating cells – including endothelial cells
(ECs) or endothelial progenitor cells (EPCs), a process known as
vasculogenesis (see the section ‘Restoration of tumour blood
vessels after irradiation’). In pre-clinical models, several investi-
gators have reported that radiation inhibits local angiogenesis, the
generation of new vessels from surrounding vessels (Udagawa
et al, 2007; Imaizumi et al, 2010). However, in these studies it is
difficult to determine whether cells, locally or distantly, mediate
tumour revascularisation after irradiation. To interrogate whether
new vasculature formation relies on a different mechanism in the
presence vs the absence of radiation, we examined the effect of
radiation on the development of tumour vasculature in the absence
of matrix metalloproteinase-9 (MMP-9), a key proangiogenic
molecule in circulating CD11bþ cells. We demonstrated that
tumours cannot grow in an irradiated site (given 20Gy) of an
MMP-9 knockout (KO) mouse but can grow in a non-irradiated
MMP-9 KO mouse. Tumour growth is restored following irradia-
tion if the bone marrow in the MMP-9 KO mouse is replaced with
wild-type bone marrow (Ahn and Brown, 2008). Thus, MMP-9
from cells in the bone marrow transplant could restore tumour
vasculature (determined by CD31 immunostaining and injection of
Hoechst dye) and support tumour growth at a pre-irradiated site.
This illustrated that revascularisation after irradiation required
extracellular matrix modelling of MMP-9 by cells in the bone
marrow, although tumour growth without irradiation did not,
suggesting that they may depend on different pathways for
recruiting new vasculature. We demonstrated through depletion
experiments and immunostaining that CD11bþ cells mediate this
effect. It is important to note that our finding that radiation
prevents local angiogenesis is not the same as the proposal of Fuks
and Kolesnick that radiation produces a rapid apoptosis of tumour
ECs and vascular shutdown (Garcia-Barros et al, 2003). We and
others who have measured tumour ECs after irradiation do not see
this rapid apoptosis (Kioi et al, 2010; Kozin et al, 2010). Rather, we
observe that ECs disappear slowly after irradiation over several
days, consistent with a mitotically linked death.
CD11bþ monocytes/macrophages are important mediators of
tumour revascuzlarisation and regrowth after irradiation. Neutra-
lising the antibodies against CD11bþ monocytes/macrophages given
after irradiation markedly enhances the antitumour effect of
radiation in human tumour xenografted mice (Ahn et al, 2010).
We observe that these monocytes also express CXCR4 on their
surface. Inhibition of the interaction of SDF-1 and CXCR4 using
the CXCR4 inhibitor, AMD3100, or antibodies against CXCR4
prevented the radiation-induced increase of CD11bþ monocytes/
macrophages and inhibited revascularisation in intracranial hu-
man GBM xenografts. Moreover, these inhibitors abrogated or
delayed the recurrence of the tumours following irradiation (Kioi
et al, 2010). Potentiation of the anticancer drug BCNU by
AMD3100 has also been shown with the intracranially implanted
U87 human glioblastoma, though the mechanism for this may have
involved abrogation of the survival function of the SDF-1/CXCR4
pathway in the tumour cells (Redjal et al, 2006) rather than
prevention of revascularisation after irradiation.
We hypothesise that elevated levels of tumour SDF-1 caused by
increased tumour hypoxia (resulting from gradual loss of ECs)
following irradiation lead to accumulation of CXCR4-expressing
monocytes/macrophages in the irradiated tumour. This is also
suggested by data in the literature showing that the recruitment
and retention of proangiogenic hematopoietic cells to sites of
ischaemic tissue damage or to tumours is mediated by the
interaction of the SDF-1 with CXCR4 (Ceradini et al, 2004; Aghi
et al, 2006; Jin et al, 2006). Stromal cell-derived factor-1 functions
as a hypoxia-inducible gene through the action of the transcription
factor hypoxia inducible factor-1 (HIF-1). We have shown that
irradiated tumours gradually lose vasculature after irradiation,
thereby becoming increasingly hypoxic and upregulating
HIF-1. Consistent with this, the HIF-1 inhibitor NSC 134754
prevents both the radiation-induced tumour accumulation of
CD11bþ monocytes/macrophages and prevents tumour recur-
rence (Kioi et al, 2010). We and others have shown that SDF-1
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et al, 2010) and in the plasma following local tumour irradiation of
intracranial GBM (unpublished data). A model showing the
pathway by which CD11bþ monocytes/macrophages accumulate
in irradiated tumours is shown in Figure 1. Also shown in Figure 1
are the points in the pathway that have been targeted therapeu-
tically to prevent the regrowth of irradiated tumours in pre-clinical
studies.
RESTORATION OF TUMOUR BLOOD VESSELS AFTER
IRRADIATION
Vasculogenesis is a term used in embryology to denote the de novo
formation of blood vessels. Its use in the present context would
imply that all the cellular components of the tumour vasculature
after irradiation come from circulating cells, not from residual
vascular cells in the tumour that survive radiation, nor from
surrounding angiogenic vessels. We hypothesise that ECs do not
regrow from surviving ECs in the radiation field at the doses used
in our studies (15–20Gy) or at TCD50 doses (doses that control
50% of the tumours) typical for transplanted tumours
(40–100Gy), and particularly in SCID mice in which all the
stromal cells are highly radiosensitive (Budach et al, 1993).
Experimental data show the importance of bone marrow-
derived CD11bþ monocytes/macrophages for the restoration
of tumour blood vessels after irradiation. Unlike CD11bþ
monocytes/macrophages in non-irradiated tumours, these cells
express the angiopoietin-2 receptor Tie-2 as well as MMP-9 and the
F4/80 macrophage marker, and are therefore classified as Tie-2-
expressing macrophages (TEMs). CD11bþ cells from an
irradiated tumour share many of the same properties as ECs and
have been shown to interact with newly forming tumour blood
vessels (De Palma et al, 2005). Whether or not there exists EPCs in
the BM that directly give rise to tumour endothelium has been a
source of controversy and confusion in the literature. To address
whether cells in the bone marrow directly give rise to the
components of blood vessels, we carefully examined the ECs in
irradiated tumours in mice with Lac-Z or GFP-expressing bone
marrow. From such studies, we and others concluded that the ECs
in the tumour do not arise from cells in the bone marrow (Ahn and
Brown, 2008; Kioi et al, 2010; Kozin et al, 2010). To our knowledge,
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Figure 1 Model of the main contributions of bone marrow-derived cells (BMDCs) and cytokines that promote restoration of tumour vasculature
following irradiation. Prior to irradiation, tumour growth is governed largely by local angiogenesis. When local angiogenesis is inhibited by irradiation, growth
of the tumour vasculature (essential for recurrence of the tumour) can only occur from circulating cells, of which BMDCs are an essential component.
Following irradiation, the tumour becomes more hypoxic and HIF-1 is increased as the tumour attempts to regrow. This induces SDF-1 and promotes the
recruitment of CD11bþ monocytes/macrophages and retention of these cells in the tumour. Stromal cell-derived factor-1/CXC chemokine receptor 4 is
the key interaction for the influx of BMDCs as AMD3100, an inhibitor of CXCR4/SDF-1, and antibodies against CXCR4 block the recruitment and/or
tumour retention of the BMDCs, inhibit restoration of the tumour vasculature, and prevent tumour recurrence. The various inhibitors and the points in the
cycle at which they act are shown in boxes. Reproduced from Kioi et al (2010) with permission. (A) Pre-irradiation; (B) post-irradiation.
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have not been shown directly to form tumour vasculature. For
instance, Purhonen et al (2008) have shown using a parabiotic
mouse system (two mice joined so as to have a common blood
supply) that VEGFR-2þ bone marrow cells did not incorporate
into the tumour endothelium. Other investigators have shown
using either orthotopic aortic allografting (Hillebrands et al, 2002)
or a parabiotic mouse system combined with reverse bone marrow
transplantation (Aicher et al, 2007) that non-bone marrow-derived
circulating ECs or EPCs from the liver and small intestine home to
sites of active angiogenesis. Thus, circulating ECs, which are not
derived from cells of the adult bone marrow, may be recruited to
the irradiated tumour. We hypothesise therefore that circulating
ECs or EPCs migrate to the irradiated tumour, thereby recon-
stituting the vasculature. Such a possibility would fit the existing
data but needs further experimental studies to validate the
hypothesis. The stimulus for this colonisation by ECs is likely to
be SDF-1 via its receptor CXCR4 (Orimo et al, 2005) and/or its
receptor CXCR7, which is highly expressed in tumour-associated
blood vessels including those in GBM (Miao et al, 2007; Liu et al,
2010). CXCR7 has also recently been shown to be co-expressed
with CXCR4 on cortical interneurons and to be essential for their
SDF-1-stimulated migration (Sanchez-Alcaniz et al, 2011).
CD11bþ cells in the irradiated tumour may also help recruit
ECs into the tumour or help reorganise the tumour extracellular
matrix via MMP-9 to mediate revascularisation. Thus, the
restoration of the tumour vasculature following radiation doses
similar to those used in cancer treatment could formally fit the
definition of vasculogenesis (i.e., derived entirely from circulating
cells), but further work is required to prove this conclusively.
Other groups have explored alternative hypotheses by which
tumours establish and/or maintain their vasculature, including
endothelial differentiation of GBM stem-like cells (Ricci-Vitiani
et al, 2010). However, markers used to define ECs can be expressed
by normal stem cells and cancer stem cells, and it does not
necessarily indicate that GBM stem cells possess plasticity towards
an EC fate. A subset of GBM stem cells may acquire features shared
by ECs when grown under EC-promoting conditions in vitro,
although this may not reflect their behaviour in vivo. Our lab has
been focusing on the mechanism of revascularisation in the post-
irradiated GBM tumour, as this can be interrupted to dramatically
improve the outcome in pre-clinical studies. We are actively
interested in identifying the source of ECs in the post-irradiated
GBM tumour.
CLINICAL DATA
Our data suggest that the pathway of post-irradiation recruitment
of CD11bþ monocytes/macrophages in tumours may be im-
portant not only in mice but also in human patients. We have
shown by immunohistochemistry that the levels of CD11bþ
monocytes/macrophages are higher in GBM recurrences than in
the same tumours prior to therapy (Kioi et al, 2010). Whether or
not these cells mediate revascularisation of human GBM after
irradiation is not yet known. However, understanding the pathway
involved in local recurrence of GBM after radiotherapy holds much
clinical potential for preventing recurrence of GBM.
Recently, a clinical study of 95 patients with GBM reported
recurrence in 79 patients (83%) after a median follow-up period of
more than 18 months. Although the majority of recurrences were
located in the radiation field, in 17 patients GBM recurred outside
the radiation field. As recurrences outside the radiation field were
observed after a longer follow-up time, different mechanisms may
be responsible for in-field and out-of-field recurrences (Minniti
et al, 2010). Blocking tumour revascularisation after irradiation
by inhibiting vasculogenesis would be the most relevant method to
prevent recurrences of GBM in the radiation field and this strategy
would benefit the majority of patients with GBM. However,
if out-of-field recurrences became the prominent pattern of
recurrence after local tumour irradiation, whole-brain irradiation
could be given, as this has been a viable clinical option for GBM
in the past. Improved markers or imaging for identifying patients
at risk for in-field vs out-of-field recurrence would allow
us to select patients who would benefit from targeted radiation
vs whole-brain irradiation. Preventing revascularisation of
tumours after irradiation would be important for both radiation
treatment strategies.
CONCLUSIONS
Stromal cell-derived factor-1 is a small pro-inflammatory chemo-
attractant cytokine that binds to its G-protein-coupled receptor
CXCR4. The interaction of SDF-1 with CXCR4 has been shown to
play a role in tumour metastasis by CXCR4-expressing tumour
cells migrating to normal tissues expressing SDF-1. In tissue
remodelling after injury, haematopoietic cells migrate to sites of
ischaemic injury, where increased levels of SDF-1 are produced
by the hypoxic upregulation of HIF-1. It has recently become
apparent that migration and recruitment of circulating proangio-
genic monocytes/macrophages can occur in tumours following
local irradiation. We have proposed that the increased
hypoxia seen in tumours following irradiation recruits CD11bþ
monocytes/macrophages and ECs to the tumour, thereby restoring
the tumour vasculature. The reliance of the tumour on revasculari-
sation after irradiation suggests a promising therapeutic approach
involving inhibition of this pathway. There are potentially a
number of ways to achieve this, including inhibition of HIF-1,
antibodies against CD11b or against CXCR4, and pharmacological
inhibition of the SDF-1/CXCR4 pathway with the drug AMD3100
(plerixafor). These strategies have been successfully used in pre-
clinical studies. Of these, the use of plerixafor is currently the most
promising for further investigations in human clinical trials as a
proof of principle, as this drug is already approved for clinical use.
Understanding the mechanism by which tumours revascularise
after irradiation offers promising therapeutic strategies for treating
GBMs.
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